$11.295
+0.13
(+1.12%)▲
Insights on Silver Spike Investment Corp
Revenue is up for the last 3 quarters, 1.64M → 3.62M (in $), with an average increase of 30.6% per quarter
Netprofit is up for the last 3 quarters, 1.21M → 2.49M (in $), with an average increase of 27.0% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 44.5% return, outperforming this stock by 13.1%
0.62%
Downside
Day's Volatility :0.88%
Upside
0.26%
44.78%
Downside
52 Weeks Volatility :44.78%
Upside
0.0%
Period | Silver Spike Investment Corp | Index (Russel 2000) |
---|---|---|
3 Months | 39.45% | 0.0% |
6 Months | 20.11% | 0.0% |
1 Year | 29.73% | 0.5% |
3 Years | -20.21% | -21.1% |
Market Capitalization | 69.0M |
Book Value | $13.77 |
Dividend Share | 0.48 |
Dividend Yield | 6.57% |
Earnings Per Share (EPS) | -0.54 |
Wall Street Target Price | 11.4 |
Profit Margin | 61.51% |
Operating Margin TTM | 66.94% |
Return On Assets TTM | 5.23% |
Return On Equity TTM | 8.53% |
Revenue TTM | 11.9M |
Revenue Per Share TTM | 1.92 |
Quarterly Revenue Growth YOY | 79.0% |
Gross Profit TTM | 5.4M |
Diluted Eps TTM | -0.54 |
Quarterly Earnings Growth YOY | 1.16 |
EPS Estimate Current Year | 0.46 |
EPS Estimate Next Year | 0.99 |
EPS Estimate Current Quarter | 0.27 |
EPS Estimate Next Quarter | 0.18 |
What analysts predicted
Upside of 0.93%
Sell
Neutral
Buy
Silver Spike Investment Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Silver Spike Investment Corp | 15.15% | 20.11% | 29.73% | -20.21% | -20.21% |
Neurocrine Biosciences Inc. | 0.91% | 23.42% | 43.73% | 57.34% | 76.99% |
Haleon Plc Spon Ads | 0.97% | 2.34% | -6.64% | 12.01% | 12.01% |
Zoetis Inc. | 0.83% | 2.39% | -9.63% | -0.27% | 61.69% |
Viatris Inc. | 0.26% | 27.9% | 19.96% | -15.43% | -27.91% |
Catalent, Inc. | -0.34% | 64.82% | 59.33% | -46.79% | 21.48% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Silver Spike Investment Corp | NA | NA | NA | 0.46 | 0.09 | 0.05 | 0.07 | 13.77 |
Neurocrine Biosciences Inc. | 56.26 | 56.26 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 30.0 | 30.0 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.76 | 29.76 | 2.58 | 5.79 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 229.4 | 229.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Silver Spike Investment Corp | Buy | $69.0M | -20.21% | NA | 61.51% |
Neurocrine Biosciences Inc. | Buy | $14.1B | 76.99% | 56.26 | 13.23% |
Haleon Plc Spon Ads | Buy | $38.4B | 12.01% | 30.0 | 9.28% |
Zoetis Inc. | Buy | $68.9B | 61.69% | 29.76 | 27.43% |
Viatris Inc. | Hold | $13.6B | -27.91% | 229.4 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 21.48% | 211.02 | -31.77% |
Jacobs Asset Management, LLC
Penserra Capital Management, LLC
Wells Fargo & Co
Organization | Silver Spike Investment Corp |
Employees | 0 |
CEO | Mr. Scott Charles Gordon |
Industry | Miscellaneous |